The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis
Abstract
Objective: There is evidence supporting a therapeutic range for methotrexate polyglutamate (MTXGlu) concentrations in the treatment of rheumatoid arthritis (RA). Knowledge of the pharmacokinetics of MTXGlu 1–5 is required for optimal timing of blood sampling. The aim of this study was to determine the time to steady state and the half‐life of accumulation of red blood cell (RBC) MTXGlu 1–5 in patients with RA commencing oral MTX, and the time for RBC MTXGlu 1–5 to become undetectable and the half‐life of elimination of RBC MTXGlu 1–5 in patients ceasing treatment with oral MTX. Methods: Ten patients beginning treatment and 10 patients stopping treatment with low‐dose oral MTX were recruited. Blood samples were initially collected weekly, with gradual extension to monthly collection over the study period. RBC MTXGlu 1–5 concentrations were assayed by high‐performance liquid chromatography. Results were analyzed using a first‐order exponential method. Results: The median times to reach steady state in RBCs (defined as 90% of the maximum concentration) were 6.2, 10.6, 41.2, 149, and 139.8 weeks, respectively, for MTXGlu 1, MTXGlu 2, MTXGlu 3, MTXGlu 4, and MTXGlu 5. The median half‐life of accumulation for RBC MTXGlu 1–5 ranged from 1.9 weeks to 45.2 weeks. The median times for MTXGlus to become undetectable in RBCs were 4.5, 5.5, 10, 6, and 4 weeks, respectively, for MTXGlu 1, MTXGlu 2, MTXGlu 3, MTXGlu 4, and MTXGlu 5. The median half‐life of elimination for RBC MTXGlu 1–5 ranged from 1.2 weeks to 4.3 weeks. Conclusion: There is wide interpatient variability of RBC MTXGlu 1–5 accumulation and elimination in adults with RA. These data also suggest that after a dose change, >6 months are required for RBC MTXGlu 1–5 to reach steady state. Such delays in achieving steady state suggest that more rapid dose escalation or subcutaneous administration from the outset should be considered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
Cited by
Side effects of methotrexate therapy for rheumatoid arthritis: A systematic review
Wang, W., Zhou, H., & Liu, L. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.09.027 · Cited by 562
The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy
Nguyen, G. C., Seow, C. H., Maxwell, C., Huang, V., Leung, Y., Jones, J., Leontiadis, G. I., Tse, F., Mahadevan, U., van der Woude, C. J., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.12.003 · Cited by 473
State-of-the-art: rheumatoid arthritis
McInnes, I. B., & O'Dell, J. R. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.134684 · Cited by 303
Park, J. K., Lee, M. A., Lee, E. Y., Song, Y. W., Choi, Y., Winthrop, K. L., & Lee, E. B. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211128 · Cited by 136
Metadata
- Authors
- Dalrymple, J. M., Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., & Barclay, M. L.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2008-10-30
- Volume
- 58
- Issue
- 11
- Pages
- 3299-3308
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2083614315
- Cited by
- 191
- References
- 1
- FWCI
- 8.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. https://app.cochat.ai/papers/10.1002/art.24034
- The paper
- Dalrymple, J. M., Stamp, L. K., O'Donnell, J. L., Chapman, P. T., Zhang, M., & Barclay, M. L. (2008). Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. Arthritis & Rheumatism. https://doi.org/10.1002/art.24034
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.